Orthocell secures European patent for its tissue regeneration technology
Important addition to the company’s current European and global IP portfolio.
The patent entitled “Method for Producing a Collagen Membrane and Uses Thereof” provides additional important intellectual property to protect the CelGro product platform.
Orthocell managing director Paul Anderson said: “This is an important addition to our current European and global IP portfolio and further strengthens our IP position.
“This comes at a perfect time for the company as we drive product adoption and sales of CelGro® in Europe.”
Patent granted in major global markets
CelGro is manufactured by Orthocell using its proprietary SMRTTM tissue engineering process, developed in conjunction with Professor Minghao Zheng and the University of Western Australia.
The customizable collagen medical device has numerous competitive advantages over existing synthetic and biologic tissue repair devices.
In addition to Europe, CelGro patents are now granted in the US, China, Canada, Singapore, Australia and New Zealand.
Global addressable market in excess of US$2.6 billion
CelGro offers significant commercial potential in its existing addressable markets of bone, tendon, nerve and cartilage as well as much wider applications in general surgical and soft tissue reconstructive applications.
The global addressable market for CelGro is in excess of US$2.6 billion and growing.